Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01730534 · ClinicalTrials.gov registry record · Phase 3
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 17,190
- Enrollment target
NCT01730534 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 17,190 participants.
The verdict
NCT01730534, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 17,190 participants
- Enrollment target
Study Summary
This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or cardiovascular risk factors.
Interventions
- DRUG Placebo tablet
- DRUG Dapagliflozin 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17,190 participants |
| Start Date | 2013-04-25 |
| Est. Completion | 2018-09-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01730534
The ClinicalTrials.gov registry entry for NCT01730534 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 17,190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo tablet is the first listed.
NCT01730534 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01730534 about?
NCT01730534 is a clinical study titled "Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events". This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or cardiovascular risk factors.
What is the current status of trial NCT01730534?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 17,190 participants. The study started on 2013-04-25. Estimated completion is 2018-09-11.
What interventions are being tested in trial NCT01730534?
The interventions under investigation include: Placebo tablet (DRUG), Dapagliflozin 10 mg (DRUG).
Who is sponsoring clinical trial NCT01730534?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.